Anti-inflammatory and pro-resolving effects of N-3 PUFA in cancers: Structures and mechanisms

Current Topics in Medicinal Chemistry

Volumn 16, Issue 8, 2016, Pages 888-894

  Wang, Qi ^a   Hu, Minghua ^b   Xu, Huibi ^a   Yang, Xiangliang ^a  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b Joint Laboratory for the Research of Chinese Herbal Polysaccharides Chinese Academy   (China)

Author keywords

Anti inflammation; Breast cancer; Colorectal cancer; Microenvironment; N 3 PUFA; Specialized pro resolving mediators

Indexed keywords

ARACHIDONATE 15 LIPOXYGENASE; CYCLOOXYGENASE 2; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LEUKOTRIENE; LINOLENIC ACID; OMEGA 3 FATTY ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; POLYUNSATURATED FATTY ACID; PROSTAGLANDIN; PROSTAGLANDIN E2; ANTINEOPLASTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT;

ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BIOAVAILABILITY; BREAST CANCER; CANCER PREVENTION; CANCER RESEARCH; COLORECTAL CANCER; ENZYME ACTIVITY; HYDROLYSIS; HYPERTRIGLYCERIDEMIA; NEOPLASM; PHOSPHOLIPID MEMBRANE; REVIEW; STRUCTURE ANALYSIS; TISSUE REGENERATION; TUMOR MICROENVIRONMENT; WOUND HEALING; CHEMISTRY; HUMAN; INFLAMMATION; MOLECULARLY TARGETED THERAPY; NEOPLASMS; PATHOPHYSIOLOGY; PROCEDURES;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; FATTY ACIDS, OMEGA-3; HUMANS; INFLAMMATION; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84973598699     PISSN: 15680266     EISSN: 18734294     Source Type: Journal    
DOI: 10.2174/1568026615666150827101602     Document Type: Review

References (75)

1. Hanahan, D.; Weinberg, R. A. Hallmarks of cancer: the next generation. Cell., 2011, 144(5), 646-674.
2. Balkwill, F.; Mantovani, A. Inflammation and cancer: back to Virchow? Lancet., 2001, 357(9255), 539-545.
3. Berquin, I. M.; Edwards, I. J.; Chen, Y. Q. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer. Lett., 2008, 269(2), 363-377.
4. Gerber, M. Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br. J. Nutr., 2012, 107(S2), S228-S239.
5. Cockbain, A. J.; Toogood, G. J. Hull, M. A. Omega-3 polyunsaturated fatty acids for the treatment and prevention of colorectal cancer. Gut., 2012, 61(1), 135-149.
6. Kang, J. X.; Liu, A. The role of the tissue omega-6/omega-3 fatty acid ratio in regulating tumor angiogenesis. Cancer. Metastasis. Rev., 2013, 32(1-2), 201-210.
7. Serhan, C. N.; Yacoubian, S.; Yang, R. Anti-inflammatory and proresolving lipid mediators. Annu. Rev. Pathol., 2008; 3,279-312.
8. Williams, C. M.; Burdge, G. Long-chain n-3 PUFA: plant v. marine sources. Proc. Nutr. Soc., 2006, 65(1), 42-50.
9. Pawlosky, R. J.; Hibbeln, J. R.; Novotny, J. A.; Salem, N. Physiological compartmental analysis of α-linolenic acid metabolism in adult humans. J. Lipid. Res., 2001, 42(8), 1257-1265.
10. Park, Y.; Harris, W. S. Omega-3 fatty acid supplementation accelerates chylomicron triglyceride clearance. J. Lipid. Res., 2003, 44(3), 455-463.
11. Arterburn, L. M.; Hall, E. B.; Oken, H. Distribution, interconversion, and dose response of n-3 fatty acids in humans. Am. J. Clin. Nutr., 2006, 83(6), 1467S-1476S.
12. Tsujita, T.; Okuda, H. The synthesis of fatty acid ethyl ester by carboxylester lipase. Eur. J. Biochem.. 1994, 224(1), 57-62.
13. Hui, D. Y.; Howles, P. N. Carboxyl ester lipase structure-function relationship and physiological role in lipoprotein metabolism and atherosclerosis. J. Lipid. Res., 2002, 43(12), 2017-2030.
14. Ikeda, I.; Sasaki, E.; Yasunami, H.; Nomiyama, S.; Nakayama, M.; Sugano, M.; Imaizumia, K.; Yazawac, K. Digestion and lymphatic transport of eicosapentaenoic and docosahexaenoic acids given in the form of triacylglycerol, free acid and ethyl ester in rats. Biochim. Biophys. Acta., 1995, 1259(3), 297-304.
15. Schuchardt, P. J.; Schneider, I.; Meyer, H.; Neubronner, J.; Schacky, C. V.; Hahn, A. Incorporation of EPA and DHA into plasma phospholipids in response to different omega-3 fatty acid formulations-a comparative bioavailability study of fish oil vs. krill oil. Lipids. Health. Dis., 2011, 10(1), 145.
16. Davidson, M. H.; Johnson, J.; Rooney, M. W.; Kyle, M. L.; Kling, D. F. A novel omega-3 free fatty acid formulation has dramatically improved bioavailability during a low-fat diet compared with omega-3-acid ethyl esters: The ECLIPSE (Epanova ® compared to Lovaza ® in a pharmacokinetic single-dose evaluation) study. J. Clin. Lipidol., 2012, 6(6), 573-584.
17. Vedtofte, M. S.; Jakobsen, M. U.; Lauritzen, L.; Heitmann, B.L. Dietary α-linolenic acid, linoleic acid, and n-3 long-chain pufa and risk of ischemic heart disease. Am. J. Clin. Nutr., 2011, 94(4), 1097-1103.
18. Mozaffarian, D.; Wu, J. H. Y. Omega-3 Fatty Acids and Cardiovascular Disease Effects on Risk Factors, Molecular Pathways, and Clinical Events. J. Am. Coll. Cardiol., 2011, 58(20), 2047-2067.
19. Itariu, B. K, Zeyda, M.; Hochbrugger, E. E.; Neuhofer, A.; Prager, G.; Schindler, K.; Bohdjalian, A.; Mascher, D.; Vangala, S.; Schranz, M.; Krebs, M.; Bischof, M. G.; Stulnig, T. M. Long-chain n-3 PUFA reduce adipose tissue and systemic inflammation in severely obese nondiabetic patients: a randomized controlled trial. Am. J. Clin. Nutr., 2012, 96(5), 1137-1149.
20. Micallef, M.; Munro, I.; Phang, M.; Manohar, G. Plasma n-3 polyunsaturated fatty acids are negatively associated with obesity. Br. J. Nutr., 2009, 102(09), 1370-1374.
21. Nettleton, J. A.; Katz, R. n-3 long-chain polyunsaturated fatty acids in type 2 diabetes: a review. J. Am. Diet. Assoc., 2005, 105(3), 428-440.
22. Mullner, E.; Brath, H.; Pleifer, S.; Schiermayr, C.; Baierl, A.; Wallner, M.; Fastian, T.; Millner, Y.; Paller, K.; Henriksen, T.; Poulsen, H. E.; Forster, E.; Wagner, K. H. Vegetables and PUFA-rich plant oil reduce DNA strand breaks in individuals with type 2 diabetes. Mol. Nutr. Food. Res., 2013, 57(2), 328-338.
23. Thun, M. J.; Henley, S. J.; Patrono, C. Nonsteroidal antiinflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J. Natl. Cancer. Inst., 2002, 94(4), 252-266.
24. Greenhough, A.; Smartt, H. J. M.; Moore A E, Roberts, H. R.; Williams, A. C.; Paraskeva, C.; Kaidi, A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 2009, 30(3), 377-386.
25. Berquin, I. M.; Edwards, I. J.; Chen, Y. Q. Multi-targeted therapy of cancer by omega-3 fatty acids. Cancer. Lett., 2008, 269(2), 363-377.
26. Kobayashi, N.; Barnard, R. J.; Henning, S. M.; Elashoff, D.; Reddy, S. T.; Cohen, P.; Leung, P.; Hong-Gonzalez, J.; Freedland, S. J.; Said, J.; Gui, D.; Seeram, N. P.; Popoviciu, L. M.; Bagga, D.; Heber, D.; Glaspy, J. A.; Aronson, W. J. Effect of altering dietary n-6/n-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin. Cancer. Res., 2006, 12(15), 4662-4670.
27. Oh, D. Y.; Talukdar, S.; Bae, E. J.; Imamura, T.; Morinaga, H.; Fan, W.; Li, P.; Lu, W. J.; Watkins, S. M.; Olefsky, J. M. GPR120 is an omega-3 fatty acid receptor mediating potent antiinflammatory and insulin-sensitizing effects. Cell., 2010, 142(5), 687-698.
28. Oh, D. Y.; Olefsky, J. M. Omega 3 fatty acids and GPR120. Cell. Metab., 2012, 15(5), 564-565.
29. Zand, H.; Rhimipour, A.; Bakhshayesh, M.; Shafiee, M.; Nour Mohammadi, I.; Salimi, S. Involvement of PPAR-γ and p53 in DHA-induced apoptosis in Reh cells. Mol. Cell. Biochem., 2007, 304(1-2), 71-77.
30. Sun, H.; Berquin, I. M.; Owens, R. T.; O'Flaherty, J. T.; Edwards, I. J. Peroxisome Proliferator-Activated Receptor γ-Mediated Upregulation of Syndecan-1 by n-3 Fatty Acids Promotes Apoptosis of Human Breast Cancer Cells. Cancer. Res., 2008, 68(8), 2912-2919.
31. Yan, Y.; Jiang, W.; Spinetti, T.; Tardivel, A.; Castillo, R.; Bourquin, C.; Guarda G.; Tian, Z.; Tschopp, J.; Zhou, R. Omega-3 fatty acids prevent inflammation and metabolic disorder through inhibition of NLRP3 inflammasome activation. Immunity., 2013, 38(6), 1154-1163.
32. Serhan, C. N.; Petasis, N. A. Resolvins and protectins in inflammation resolution. Chem. Rev., 2011, 111(10), 5922-5943.
33. Serhan, C. N.; Pro-resolving lipid mediators are leads for resolution physiology. Nature., 2014, 510(7503), 92-101.
34. Assignment, S.; Antiinflammatory Properties, and Receptor for the Omega-3 Lipid Mediator Resolving E1. J. Exp. Med., 2005, 201(5), 713-722.
35. Serhan, C. N.; Dalli, J.; Karamnov, S.; Choi, A.; Park, C. K.; Xu, Z. Z.; Ji, R. R.; Zhu, M.; Petasis, N. A. Macrophage proresolving mediator maresin 1 stimulates tissue regeneration and controls pain. FASEB. J., 2012, 26(4), 1755-1765.
36. Polavarapu, S.; Mani, A. M.; Gundala, N. K.; Hari, A. D.; Bathina, S.; Das, U. N. Effect of Polyunsaturated Fatty Acids and Their Metabolites on Bleomycin-Induced Cytotoxic Action on Human Neuroblastoma Cells In Vitro. PLoS. One., 2014, 9(12), e114766
37. Lee, H. J.; Park, M. K.; Lee, E. J.; Lee, C. H. Resolvin D1 inhibits TGF-1-induced epithelial mesenchymal transition of A549 lung cancer cells via lipoxin A4 receptor/formyl peptide receptor 2 and GPR32. Int. J. Biochem. Cell. Biol., 2013, 45(12), 2801-2807.
38. Aursnes, M.; Tungen, J. E.; Vik, A.; Colas, R.; Cheng, C. Y.; Dalli, J.; Serhan, C. N.; Hansen, T. V. Total Synthesis of the Lipid Mediator PD1 n-3 DPA: Configurational Assignments and Antiinflammatory and Pro-resolving Actions. J. Nat. Prod., 2014, 77(4), 910-916.
39. Rodriguez, A. R.; Spur, B. W. Total synthesis of the potent antiinflammatory lipid mediator Protectin D1. Tetrahedron. Lett., 2014, 55(43), 6011-6015.
40. Rodriguez, A. R.; Spur, B. W. Total synthesis of Resolvin D1, a potent anti-inflammatory lipid mediator. Tetrahedron. Lett., 2012, 53(51), 6990-6994.
41. Rodriguez, A. R.; Spur, B. W. First total synthesis of 7 (S), 16 (R), 17 (S)-Resolvin D2, a potent anti-inflammatory lipid mediator. Tetrahedron. Lett., 2004, 45(47), 8717-8720.
42. Li, J.; Leong, M. M.; Stewart, A.; Rizzacasa, M. A. Total synthesis of the endogenous inflammation resolving lipid resolvin D2 using a common lynchpin. Beilstein. J. Org. Chem., 2013, 9(1), 2762-2766.
43. Winkler, J. W.; Uddin, J.; Serhan, C. N.; Petasis, N. A. Stereocontrolled Total Synthesis of the Potent Anti-inflammatory and Proresolving Lipid Mediator Resolvin D3 and Its Aspirin-Triggered 17 R-Epimer. Org. Lett., 2013, 15(7), 1424-1427.
44. Rodriguez, A. R.; Spur, B. W. First total synthesis of 7 (S), 17 (S)- Resolvin D5, a potent anti-inflammatory docosanoid. Tetrahedron. Lett., 2005, 46(21), 3623-3627.
45. Rodriguez, A. R.; Spur, B. W. First total synthesis of the antiinflammatory lipid mediator Resolvin D6. Tetrahedron. Lett., 2012, 53(1), 86-89.
46. Ogawa, N.; Kobayashi, Y. Total synthesis of resolvin E1. Tetrahedron. Lett., 2009, 50(44), 6079-6082.
47. Ogawa, S.; Urabe, D.; Yokokura, Y.; Arai, H.; Arita, M.; Inoue, M. Total synthesis and bioactivity of resolvin E2. Org. Lett., 2009, 11(16), 3602-3605.
48. Rodriguez, A. R.; Spur, B. W. Total synthesis of the antiinflammatory lipid mediator Resolvin E2. Tetrahedron. Lett., 2012, 53(15), 1912-1915.
49. Urabe, D.; Todoroki, H.; Masuda K.; Inoue, M. Total syntheses of four possible stereoisomers of resolvin E3. Tetrahedron., 2012, 68(15), 3210-3219.
50. Rodriguez, A. R.; Spur, B. W. Total synthesis of the macrophage derived anti-inflammatory lipid mediator Maresin 1. Tetrahedron. Lett., 2012, 53(32), 4169-4172.
51. Ogawa, N.; Kobayashi, Y. Total synthesis of the antiinflammatory and proresolving protectin D1. Tetrahedron. Lett., 2011, 52(23), 3001-3004.
52. Aursnes, M.; Tungen, J. E. Vik, A.; Dalli, J.; Hansen, T. V. Stereoselective synthesis of protectin D1: a potent anti-inflammatory and proresolving lipid mediator. Org. Biomol. Chem., 2014, 12(3), 432-437.
53. Gerber, M. Omega-3 fatty acids and cancers: a systematic update review of epidemiological studies. Br. J. Nutr., 2012, 107(S2), S228-S239.
54. Carayol, M.; Grosclaude, P.; Delpierre, C. Prospective studies of dietary alpha-linolenic acid intake and prostate cancer risk: a metaanalysis. Cancer. Causes. Control., 2010, 21(3), 347-355.
55. Theodoratou, E.; McNeill, G.; Cetnarskyj, R.; Farrington, S. M.; Tenesa, A.; Barnetson, R.; Porteous, M.; Dunlop, M.; Campbell, H. Dietary fatty acids and colorectal cancer: a case-control study. Am. J. Epidemiol., 2007, 166(2), 181-195.
56. Kim, S.; Sandler, D. P.; Galanko, J.; Martin, C.; Sandler, R. S. Intake of polyunsaturated fatty acids and distal large bowel cancer risk in whites and African Americans. Am. J. Epidemiol., 2010, 171(9), 969-979.
57. Daniel, C. R.; McCullough, M. L.; Patel, R. C.; Jacobs, E. J.; Flanders, W. D.; Thun, M. J.; Calle, E. E. Dietary intake of ω-6 and ω-3 fatty acids and risk of colorectal cancer in a prospective cohort of US men and women. Cancer. Epidemiol. Biomarkers. Prev., 2009, 18(2), 516-525.
58. Thiébaut, A.; Chajès, V.; Gerber, M.; Boutron-Ruault, M. C.; Joulin, V.; Lenoir, G.; Berrino, F.; Riboli, E.; Bénichou, J.; Clavel-Chapelon, F. Dietary intakes of ω-6 and ω-3 polyunsaturated fatty acids and the risk of breast cancer. Int. J. Cancer., 2009, 124(4), 924-931.
59. Kuriki, K.; Hirose, K.; Wakai, K.; Matsuo, K.; Ito, H.; Suzuki, T.; Hiraki, A.; Saito, T.; Iwata, H.; Tatematsu, M.; Tajima, K. Breast cancer risk and erythrocyte compositions of n-3 highly unsaturated fatty acids in Japanese. Int. J. Cancer., 2007, 121(2), 377-385.
60. Shannon, J.; King, I. B.; Moshofsky, R.; Lampe, J. W.; Gao, D. L.; Ray, R. M.; Thomas, D. B. Erythrocyte fatty acids and breast cancer risk: a case-control study in Shanghai, China. Am. J. Clin. Nutr., 2007, 85(4), 1090-1097.
61. Murff, H. J.; Shu, X. O.; Li, H.; Yang, G.; Wu, X.; Cai, H.; Wen, W.; Gao, Y. T.; Zheng, W. Dietary polyunsaturated fatty acids and breast cancer risk in Chinese women: a prospective cohort study. Int. J. Cancer., 2011, 128(6), 1434-1441.
62. Witt, P. M.; Christensen, J. H.; Schmidt, E. B.; Dethlefsen, C.; Tjonneland, A.; Overvad, K.; Ewertz, M. Marine n-3 polyunsaturated fatty acids in adipose tissue and breast cancer risk: a case- cohort study from Denmark. Cancer. Causes. Control., 2009, 20(9), 1715-1721.
63. Daniel, C. R.; McCullough, M. L.; Patel, R. C.; Jacobs, E. J.; Flanders, W. D.; Thun, M. J.; Calle, E. E. Dietary intake of n-6 and n-3 fatty acids and risk of colorectal cancer in a prospective cohort of US men and women. Cancer. Epidemiol. Biomarkers. Prev., 2009, 18(2), 516-525.
64. Hall, M. N.; Chavarro, J. E.; Lee, I. M.; Willett, W. C.; Ma, J. A 22-year prospective study of fish, n-3 fatty acid intake, and colorectal cancer risk in men. Cancer. Epidemiol. Biomarkers. Prev., 2008, 17(5), 1136-1143.
65. Rothwell, P. M.; Wilson, M.; Elwin, C. E.; Norrving, B.; Algra, A.; Warlow, C. P.; Meade, T. W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet., 2010, 376(9754), 1741-1750.
66. Wigmore, S. J.; Barber, M. D.; Ross, J. A.; Tisdale, M. J. Fearon, K. C. Effect of oral eicosapentaenoic acid on weight loss in patients with pancreatic cancer. Nutr. Cancer., 2000, 36(2), 177-184.
67. Mantovani, G.; Maccio, A.; Madeddu, C.; Gramignano, G.; Lusso, M. R.; Serpe, R.; Massa, E.; Astara, G.; Deiana, L. A phase II study with antioxidants, both in the diet and supplemented, pharmaconutritional support, progestagen, and anti-cyclooxygenase-2 showing efficacy and safety in patients with cancer-related anorexia/ cachexia and oxidative stress. Cancer. Epidemiol. Biomarkers. Prev., 2006, 15(5), 1030-1034.
68. Klek, S., Kulig, J.; Szczepanik, A. M.; Jedrys, J.; Kołodziejczyk, P. The clinical value of parenteral immunonutrition in surgical patients. Acta. Chir. Belg., 2005, 105(2), 175-179.
69. Nakamura, K.; Kariyazono, H.; Komokata, T. Hamada, N. Sakata, R.; Yamada, K. Influence of preoperative administration of ω-3 fatty acid-enriched supplement on inflammatory and immune responses in patients undergoing major surgery for cancer. Nutr., 2005, 21(6), 639-649.
70. Aiko, S.; Yoshizumi, Y.; Tsuwano, S.; Shimanouchi, M.; Sugiura, Y.; Maehara, T. The effects of immediate enteral feeding with a formula containing high levels of ω-3 fatty acids in patients after surgery for esophageal cancer. JPEN. J. Parenter. Enteral. Nutr., 2005, 29(3), 141-147.
71. Heller, A. R.; Rossel, T.; Gottschlich, B.; Tiebel, O.; Menschikowski, M.; Litz, R. J.; Zimmermann, T.; Koch, T. Omega-3 fatty acids improve liver and pancreas function in postoperative cancer patients. International Journal of Cancer, 2004, 111(4), 611-616.
72. Solomon, S. D.; McMurray, J. J.; Pfeffer, M. A.; Wittes, J.; Fowler, R.; Finn, P.; Anderson, W. F.; Zauber, A.; Hawk, E.; Bertagnolli, M.; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N. Engl. J. Med., 2005, 352(11), 1071-1080.
73. Larsson, S. C.; Kumlin, M.; Ingelman-Sundberg, M.; Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am. J. Clin. Nutr., 2004, 79(6), 935-945.
74. Roynette, C. E.; Calder, P. C.; Dupertuis, Y. M.; Pichard, C. n-3 polyunsaturated fatty acids and colon cancer prevention. Clin. Nutr., 2004, 23(2), 139-151.
75. Coussens LM, Werb Z. Inflammation and cancer. Nature., 2002, 420(6917), 860-867.